In this issue:
Intensified vs. standard infliximab induction for steroid-refractory acute severe UC
Harms with placebo in induction biologic/small molecule trials in IBD
Upadacitinib vs. vedolizumab, ustekinumab and tofacitinib for UC
Ustekinumab and adalimumab persistence for UC according to advanced therapy experience
Inflammatory eye disease: risk factor for microscopic colitis
Stricturing, penetrating complications and extraintestinal manifestations in IBD
Degree of bowel remission predicts phenotype progression in CD
Lymphoma risk in patients with IBD
Early ileal resection in CD: no association with severe long-term outcomes
Upadacitinib after tofacitinib for IBD
Please login below to download this issue (PDF)